Stanley Laman Group Ltd. Has $272,000 Position in Johnson & Johnson (NYSE:JNJ)

Stanley Laman Group Ltd. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,733 shares of the company’s stock after selling 173 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Johnson & Johnson were worth $272,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in JNJ. LaFleur & Godfrey LLC boosted its holdings in shares of Johnson & Johnson by 4.9% during the third quarter. LaFleur & Godfrey LLC now owns 118,918 shares of the company’s stock worth $18,521,000 after purchasing an additional 5,585 shares during the period. Hanlon Investment Management Inc. lifted its stake in Johnson & Johnson by 46.3% in the third quarter. Hanlon Investment Management Inc. now owns 2,081 shares of the company’s stock valued at $324,000 after acquiring an additional 659 shares during the last quarter. Kessler Investment Group LLC lifted its stake in Johnson & Johnson by 1.9% in the third quarter. Kessler Investment Group LLC now owns 52,455 shares of the company’s stock valued at $8,170,000 after acquiring an additional 974 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in Johnson & Johnson by 1.5% in the third quarter. Proficio Capital Partners LLC now owns 21,097 shares of the company’s stock valued at $3,286,000 after acquiring an additional 306 shares during the last quarter. Finally, Capital Advisory Group Advisory Services LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $1,260,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reduced their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 17th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 1.5 %

Shares of JNJ stock opened at $144.61 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm’s fifty day simple moving average is $154.80 and its 200 day simple moving average is $155.14. The firm has a market capitalization of $348.48 billion, a P/E ratio of 9.02, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the firm posted $2.68 earnings per share. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is presently 29.68%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.